Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
PLoS One. 2012;7(4):e34150. doi: 10.1371/journal.pone.0034150. Epub 2012 Apr 17.
We present the results of a global study of dysregulated miRNAs in paired samples of normal mucosa and tumor from eight patients with colorectal cancer. Although there is existing data of miRNA contribution to colorectal tumorigenesis, these studies are typically small to medium scale studies of cell lines or non-paired tumor samples. The present study is to our knowledge unique in two respects. Firstly, the normal and adjacent tumor tissue samples are paired, thus taking into account the baseline differences between individuals when testing for differential expression. Secondly, we use high-throughput sequencing, thus enabling a comprehensive survey of all miRNAs expressed in the tissues. We use Illumina sequencing technology to perform sequencing and two different tools to statistically test for differences in read counts per gene between samples: edgeR when using the pair information and DESeq when ignoring this information, i.e., treating tumor and normal samples as independent groups. We identify 37 miRNAs that are significantly dysregulated in both statistical approaches, 19 down-regulated and 18 up-regulated. Some of these miRNAs are previously published as potential regulators in colorectal adenocarcinomas such as miR-1, miR-96 and miR-145. Our comprehensive survey of differentially expressed miRNAs thus confirms some existing findings. We have also discovered 16 dysregulated miRNAs, which to our knowledge have not previously been associated with colorectal carcinogenesis: the following significantly down-regulated miR-490-3p, -628-3p/-5p, -1297, -3151, -3163, -3622a-5p, -3656 and the up-regulated miR-105, -549, -1269, -1827, -3144-3p, -3177, -3180-3p, -4326. Although the study is preliminary with only eight patients included, we believe the results add to the present knowledge on miRNA dysregulation in colorectal carcinogenesis. As such the results would serve as a robust training set for validation of potential biomarkers in a larger cohort study. Finally, we also present data supporting the hypothesis that there are differences in miRNA expression between adenocarcinomas and neuroendocrine tumors of the colon.
我们呈现了一项针对 8 名结直肠癌患者的正常黏膜和肿瘤配对样本中失调 miRNA 的全球研究结果。虽然已经有 miRNA 促进结直肠肿瘤发生的现有数据,但这些研究通常是细胞系或非配对肿瘤样本的中小规模研究。本研究在两个方面是独一无二的。首先,正常和相邻肿瘤组织样本是配对的,因此在测试差异表达时考虑了个体之间的基线差异。其次,我们使用高通量测序,从而能够全面调查组织中表达的所有 miRNA。我们使用 Illumina 测序技术进行测序,并使用两种不同的工具来统计测试样本中每个基因的读取计数差异:使用配对信息时使用 edgeR,忽略此信息时使用 DESeq,即肿瘤和正常样本作为独立组。我们确定了在这两种统计方法中都显著失调的 37 个 miRNA,其中 19 个下调,18 个上调。其中一些 miRNA 以前被发表为结直肠腺癌的潜在调节剂,如 miR-1、miR-96 和 miR-145。我们对差异表达 miRNA 的全面调查因此证实了一些现有发现。我们还发现了 16 个失调的 miRNA,据我们所知,这些 miRNA 以前与结直肠癌发生无关:以下显著下调的 miR-490-3p、-628-3p/-5p、-1297、-3151、-3163、-3622a-5p、-3656 和上调的 miR-105、-549、-1269、-1827、-3144-3p、-3177、-3180-3p、-4326。尽管这项研究只有 8 名患者参与,初步的,但我们认为这些结果增加了结直肠癌发生中 miRNA 失调的现有知识。因此,这些结果将作为在更大队列研究中验证潜在生物标志物的稳健训练集。最后,我们还提供了支持以下假设的证据:即结肠腺癌和神经内分泌肿瘤之间的 miRNA 表达存在差异。